The advent of voretigene neparvovec, the first approved gene therapy for RPE65-associated IRDs, heralded a new epoch in ophthalmology and has given hope to patients suffering from these devastating conditions. The gene discussed is RPE65; the disease is respiratory distress syndrome in premature infants.